Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28662033 | 0.81 | THRB (0.38) | THRBCYP2C19ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL6284319 | 0.79 | THRB (0.40) | THRBCYP2C19ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL285117 | 0.78 | THRB (0.50) | THRBCYP2C19ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL285628 | 0.77 | HCAR2 (0.39) | THRBCYP2C19ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL717688 | 0.76 | ALDH1A1 (0.41) | CYP2C19ALDH1A1CYP3A4CYP2C9TGM2 | |
| SCHEMBL285105 | 0.74 | TSHR (0.49) | THRBALDH1A1CYP3A4HIF1ATHRA | |
| SCHEMBL285067 | 0.74 | TSHR (0.49) | THRBALDH1A1CYP3A4HIF1ATHRA | |
| SCHEMBL3169549 | 0.71 | CYP2C19 (0.46) | THRBCYP2C19ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL717487 | 0.71 | TGM2 (0.46) | CYP2C19ALDH1A1CYP3A4CYP2C9TGM2 | |
| SCHEMBL718737 | 0.70 | CYP2C19 (0.37) | THRBCYP2C19ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729203-B2 | Polymer composition | CONTAMAC LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2427509-A1 | POLYMER COMPOSITION | Contamac Limited (GB) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010128266-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | THRB 4392/4885CYP2C19 1029/4885ALDH1A1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.